Christine Regan Lindenboom | Alnylam Pharmaceuticals, Inc. |
John M. Maraganore | Alnylam Pharmaceuticals, Inc. |
Akshay K. Vaishnaw | Alnylam Pharmaceuticals, Inc. |
Manmeet Singh Soni | Alnylam Pharmaceuticals, Inc. |
Barry E. Greene | Alnylam Pharmaceuticals, Inc. |
Yvonne L. Greenstreet | Alnylam Pharmaceuticals, Inc. |
Terence Flynn | Goldman Sachs & Co. LLC |
Ted A. Tenthoff | Piper Jaffray & Co. |
Gena Wang | Barclays Capital, Inc. |
Madhu Kumar | B. Riley FBR, Inc. |
Vincent Chen | Sanford C. Bernstein & Co. LLC |
Maury Raycroft | Jefferies LLC |
Alan Carr | Needham & Co. LLC |
Irina Margine | Cowen and Company |
David N. Lebowitz | Morgan Stanley & Co. LLC |
Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals Conference Call to discuss First Quarter 2018 Financial Results. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the Company's request. I would now like turn the call over to the Company.
Good afternoon.